Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors

Table 1

Baseline characteristic.

	Immunotherapy ()				Chemotherapy ()	value
	Pembrolizumab ()	Camrelizumab ()	Atezolizumab ()	Nivolumab ()
Characteristic
Age, median (range)	63 (50-77)	66 (40-75)	67 (43-78)	68 (39-75)	62 (40-75)	0.4158
Men	9	16	16	15	35	0.7747
Women	3	7	3	4	10
ECOG performance status score
0	4	6	7	5	15	0.7162
1	8	17	12	14	30
Tumor histological features
Squamous	4	8	6	6	14	0.8420
Nonsquamous	8	15	13	13	31
TNM stage
III	5	7	7	6	15	0.9189
IV	7	16	12	13	30